Clostridium difficile infection (CDI) refers to the disease caused by the toxins produced by the spore forming bacterium clostridium difficile, in the large intestine of the human body. In many hospitals and other healthcare facilities, it is among the most common cause of antibiotic-associated diarrhea, where the spectrum ranges from mild, self-limiting diarrhea, to serious diarrhea, pseudomembranous colitis, and life-threatening fulminant colitis, which usually results in death. Several new strains of CDI are being reported in developed markets, such as the United States, Europe, and Canada, which produces large quantities of toxins A and B, leading to higher mortality rate.
This report by Mordor Intelligence provides extensive insights of the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world are provided, with data obtained from multiple sources. The report also comprises of a list of key sponsors, having pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and in-house team of research experts. The pipeline assessment reports are generated, based on the information procured from various stake holders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research are validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports are continuously updated, to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation, by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation, by Status
7.6 Other Statuses
8. Pipeline Therapeutic Assessment (Infographic Charts and Brief description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence